Iradimed Projects Q4 Revenue Between $25M and $26.5M Driven by 3870 MR IV Pump Growth
Iradimed (IRMD) has issued optimistic revenue guidance for the fourth quarter, projecting between $25 million and $26.5 million. This forecast is driven by the strong market performance of the new 3870 MR IV pump, which management expects to achieve more than 50% sequential growth. CEO Roger Susi expressed high confidence in the product launch, noting that the 3870 pump's performance has exceeded initial company expectations. The successful rollout of this technology is positioned as a primary catalyst for the company's upcoming financial results.
Tickers: $IRMD